Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

Targeted Metabolomics Finds Its Mark in Diabetes Research

  1. James R. Bain⇓
  1. Metabolomics Laboratory, Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina,
  2. Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, North Carolina
  1. Corresponding author: James R. Bain, james.bain{at}duke.edu.
Diabetes 2013 Feb; 62(2): 349-351. https://doi.org/10.2337/db12-1189
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Numerous biochemical pathways are deranged in diabetes, especially those involving metabolic fuels. Metabolomics, which seeks to simultaneously measure many small molecules, shows promise as a source of mechanistic insight into the molecular pathology of diabetes (1), but no systematic approach has yet come into wide use. Methods vary greatly from laboratory to laboratory. For most of the last decade, metabolomic studies in diabetes have been dominated by nontargeted methods in which nuclear magnetic resonance spectroscopy (NMR) or mass spectrometry (MS) are used to gather large and complex datasets from which investigators extract information on metabolites that characterize a biological condition of interest (2–8). Our own approach has centered on targeted MS methods, in which labeled internal standards are used in conjunction with narrowly focused instrumental methods to yield quantitative data on panels of chemically similar metabolites (1,9–20). Some critics do not consider such targeted studies to be “metabolomics” at all. Targeted metabolomic studies are on the rise in diabetes research (13–15,18), and an increasing number of laboratories combine both approaches or fashion hybrids of the two (16,17,19).

This month’s issue of Diabetes includes an account of one of the largest targeted metabolomic studies of human diabetes reported to date. Floegel et al. (13) propose a model of the 7-year risk of developing type 2 diabetes (T2D) based on circulating metabolites measured at baseline in initially healthy subjects enrolled in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam (a subcohort of 2,282 individuals, compared with all 800 incident cases of T2D). This model was then partially validated in the Cooperative Health Research in the Region of Augsburg (KORA) study (n = 876; 91 with incident T2D), and related to insulin secretion and sensitivity using samples from the Tübingen Family Study (TüF; n = 76). Their results confirm and extend contemporary findings in independent studies.

Flow-injection, tandem MS (FI-MS/MS) identified 163 circulating metabolites. Elevations in phenylalanine, tyrosine, isoleucine, and valine associated with increased risk of T2D (Fig. 1). This corroborates results of recent metabolomic studies that linked increases in the three branched-chain amino acids (namely isoleucine, valine, and leucine) and the aromatic amino acids (phenylalanine, tyrosine, histidine, and tryptophan) with obesity and T2D (3–5,7,8,10–12,16,19,20). Further work is needed to determine whether these amino acids are elevated because of host genetics, diet, or the actions of gut microbes (14). Studies in laboratory animals raise suspicion that these amino acids, especially the branched-chain amino acids, might have a causal role in the development of insulin resistance (11). Glycine was an enigma—alone among the amino acids, it correlated negatively with T2D risk. We and others (3,8,11,17,20) have noted lower glycine levels in patients with obesity, impaired insulin sensitivity, or both. In examining samples from these patients, we have grown accustomed to seeing elevations of circulating metabolites that cut across a broad diversity of biochemical pathways, a global signature of disordered metabolic homeostasis—and time and again, glycine stands out as a maverick, trending in the opposite direction. Floegel et al. speculate that glycine depletion in patients at risk for T2D might result from diversion to gluconeogenesis, increased biosynthesis of glutathione to combat oxidative stress, or its use to dispose of incompletely oxidized metabolites as urinary acylglycines.

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Circulating metabolites associated with the 7-year risk of developing T2D (13). Growing evidence links elevated aromatic and branched-chain amino acids to the onset of insulin-resistant states, but the reasons these metabolites are enriched remain obscure. Repletion of 6-carbon sugars other than glucose might pose independent risks. Patients at risk for T2D have reduced levels of glycine, possibly from making glutathione to combat oxidative stress or the need to conjugate and excrete incompletely oxidized fuels. PC-based lipids tell a complex story that might involve signal transduction, liver function, and oxidative stress.

The FI-MS/MS method they used cannot distinguish glucose from its isomeric hexoses, but the positive association between the hexose feature and T2D risk remained after correction for glucose measurements made by another analytic method, suggesting that fructose and perhaps such minor hexoses as mannose and galactose might be independent risk factors.

Phosphocholine (PC)-containing lipids were also informative (Fig. 1). Risk of T2D correlated positively with four species of diacylphosphatidylcholines, especially those in which fatty acid residues were shorter and had lower degrees of saturation. Similarly, in a recent NMR metabolomic study of insulin resistance (using homeostasis model assessment of insulin resistance) in more than 7,000 human subjects, Würtz et al. (7) found a positive association between insulin resistance and an NMR feature that reports an aggregate of PC-containing metabolites. Conversely, T2D risk correlated negatively with palmitoleoyl sphingomyelin, linoleoyl lysophosphatidylcholine (15), and five PC-based plasmalogens (acyl-alkyl PCs; 18). Future studies should evaluate the potential roles of these PC lipids in such processes as hepatic lipid secretion, signal transduction, and, in the case of the plasmalogens, resistance to oxidation of unsaturated lipids (Fig. 1).

The subtle metabolic phenotype defined by these metabolites significantly improved prediction of T2D risk compared with the use of such established biomarkers as glucose and HbA1c. Surprisingly, basic features of this metabolic signature of T2D risk could be discerned regardless of whether blood was drawn at random or with the donor in a fasting state. (KORA sera and TüF plasmas were from fasting subjects, whereas most EPIC-Potsdam sera were random). If this observation is verified in follow-on studies, then blood products from random phlebotomies archived in biobanks might be more useful for metabolomic studies of diabetes than one might have thought.

Multiplexed measurement of dozens to hundreds of metabolites by NMR or MS remains fraught with technical difficulties. The study by Floegel et al. (13) is significant in that it is one of the first large population studies of diabetes in which a commercial kit was used to conduct targeted, MS-based metabolomics. Encouragingly, batch effects, which can be the demons of any large metabolomic study, were controllable, with coefficients of variation between plates of less than 12% in the EPIC-Potsdam sera. These investigators are experienced with this FI-MS/MS kit (4), and they are alert to such potentially confounding effects as ion suppression and interferences (13), but suitability of such kits for use by more casual users is an open question. Their elucidation of a phenotype of T2D risk involving circulating amino acids and PC lipids shows that targeted metabolomics is coming into its own. This engenders hope that forthcoming data on metabolites, when integrated with knowledge gleaned from genomics, transcriptomics, and proteomics, will help to deliver on the promise of functional genomics and translational medicine in diabetes.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health Grant P30-AG028716.

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying original article, p. 639.

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Bain JR,
    2. Stevens RD,
    3. Wenner BR,
    4. Ilkayeva O,
    5. Muoio DM,
    6. Newgard CB
    . Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 2009;58:2429–2443pmid:19875619
    OpenUrlFREE Full Text
  2. ↵
    1. Dutta T,
    2. Chai HS,
    3. Ward LE,
    4. et al
    . Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes 2012;61:1004–1016pmid:22415876
    OpenUrlCrossRefPubMed
  3. ↵
    1. Fiehn O,
    2. Garvey WT,
    3. Newman JW,
    4. Lok KH,
    5. Hoppel CL,
    6. Adams SH
    . Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 2010;5:e15234pmid:21170321
    OpenUrlCrossRefPubMed
  4. ↵
    1. Suhre K,
    2. Meisinger C,
    3. Döring A,
    4. et al
    . Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010;5:e13953pmid:21085649
    OpenUrlCrossRefPubMed
  5. ↵
    Temmerman L, De Livera AM, Bowne JB, et al. Cross-platform urine metabolomics of experimental hyperglycemia in type 2 diabetes. J Diabetes Metab. In press
    1. van der Kloet FM,
    2. Tempels FW,
    3. Ismail N,
    4. et al
    . Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012;8:109–119pmid:22279428
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Würtz P,
    2. Mäkinen VP,
    3. Soininen P,
    4. et al
    . Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012;61:1372–1380pmid:22511205
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Würtz P,
    2. Tiainen M,
    3. Mäkinen VP,
    4. et al
    . Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 2012;35:1749–1756pmid:22563043
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kim DH,
    2. Sartor MA,
    3. Bain JR,
    4. et al
    . Rapid and weight-independent improvement of glucose tolerance induced by a Peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes 2012;61:2299–2310pmid:22733798
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Laferrère B, Reilly D, Arias S, et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med 2011;3:80re2
  10. ↵
    1. Newgard CB,
    2. An J,
    3. Bain JR,
    4. et al
    . A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311–326pmid:19356713
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Shah SH,
    2. Crosslin DR,
    3. Haynes CS,
    4. et al
    . Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia 2012;55:321–330pmid:22065088
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Floegel A,
    2. Stefan N,
    3. Yu Z,
    4. et al
    . Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013;62:639–648
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Shah SH,
    2. Svetkey LP,
    3. Newgard CB
    . Branching out for detection of type 2 diabetes. Cell Metab 2011;13:491–492pmid:21531330
    OpenUrlCrossRefPubMed
  14. ↵
    1. Barber MN,
    2. Risis S,
    3. Yang C,
    4. et al
    . Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE 2012;7:e41456pmid:22848500
    OpenUrlCrossRefPubMed
  15. ↵
    1. Cheng S,
    2. Rhee EP,
    3. Larson MG,
    4. et al
    . Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012;125:2222–2231pmid:22496159
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Escobar-Morreale HF,
    2. Samino S,
    3. Insenser M,
    4. et al
    . Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem 2012;58:999–1009pmid:22427353
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Pietiläinen KH,
    2. Sysi-Aho M,
    3. Rissanen A,
    4. et al
    . Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects—a monozygotic twin study. PLoS ONE 2007;2:e218pmid:17299598
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wang TJ,
    2. Larson MG,
    3. Vasan RS,
    4. et al
    . Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448–453pmid:21423183
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Huffman KM,
    2. Shah SH,
    3. Stevens RD,
    4. et al
    . Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009;32:1678–1683pmid:19502541
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes: 62 (2)

In this Issue

February 2013, 62(2)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeted Metabolomics Finds Its Mark in Diabetes Research
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeted Metabolomics Finds Its Mark in Diabetes Research
James R. Bain
Diabetes Feb 2013, 62 (2) 349-351; DOI: 10.2337/db12-1189

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Targeted Metabolomics Finds Its Mark in Diabetes Research
James R. Bain
Diabetes Feb 2013, 62 (2) 349-351; DOI: 10.2337/db12-1189
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lifting the Veil on the “Phosphate Flush,” a Cryptic Phenomenon of Experimental Pancreatic Islet Physiology
  • Window of Opportunity: Targeting ANGPTL4 Improves Triglyceride Levels in Maternal Obesity During Pregnancy
  • New Antidiabetes Agent Targeting Both Mitochondrial Uncoupling and Pyruvate Catabolism: Two Birds With One Stone
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.